Janssen Research & Development, Llc

This study is testing a new drug called amivantamab, both alone and in combination with other cancer medications, for people with advanced head and neck cancer. The main goals are to find safe doses and see if these treatments can shrink tumors or help patients live longer. It wi…

This study is testing different ways to give the drug ibrutinib, either alone or with another drug called venetoclax, to people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to find dosing strategies that effectively…

This study is testing whether adding an experimental immune therapy called pasritamig to standard chemotherapy (docetaxel) works better than chemotherapy alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The main goal is to see…

This study follows people who previously received an experimental eye injection treatment for geographic atrophy, a condition that causes progressive vision loss. The main goal is to monitor long-term safety by tracking any side effects or problems that develop over time. Only pe…

This study is testing whether adding a new drug called seltorexant to standard antidepressants helps adults and elderly patients who have major depression along with insomnia. The goal is to see if it improves depression symptoms and sleep better than a placebo, and if the benefi…

This study is checking the long-term safety of guselkumab in children who already benefited from it in previous studies. It includes 196 children with Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. The main goal is to see if the drug remains safe when used …

This study is testing whether two different drug combinations can help control advanced lung cancer that has specific genetic changes. The trial will involve 480 people with advanced non-small cell lung cancer who have either never received treatment before or have tried one prev…

This early-stage study is testing a new drug called JNJ-89853413 for adults with acute myeloid leukemia or myelodysplastic neoplasms that have returned or stopped responding to previous treatments. The main goals are to find a safe dose and see how the body processes the drug. Re…

This study is testing whether an experimental drug called JNJ-88545223 can help control the symptoms of active psoriatic arthritis. About 240 adults with this condition will receive either the drug or a placebo for 16 weeks to see if it reduces joint swelling, tenderness, and ski…

This study is testing an investigational drug called JNJ-95597528 to see if it can reduce the skin rash and severe itching of moderate-to-severe eczema (atopic dermatitis). About 180 adult participants will receive either the drug or a placebo for 12 weeks to compare effectivenes…

This study is testing whether a drug called nipocalimab can help control chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that causes progressive weakness and disability. The trial will enroll about 201 adults with CIDP to see if nipocalimab can delay the ret…

This study is testing an experimental drug called JNJ-79635322 for people with multiple myeloma, a blood cancer, that has come back or stopped responding to at least three prior standard treatments. The main goal is to see how well the drug works to control the cancer and measure…

This is the first study in humans to test a new drug called JNJ-90189892. It aims to find a safe and effective dose for adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not responded to prior treatments. The study will first determine the safest dos…

This study is testing a new drug delivery system called TAR-210, which is a small implant placed in the bladder to slowly release a targeted cancer drug. It is being compared to standard liquid chemotherapy placed directly into the bladder. The goal is to see which treatment is b…

This study aims to find better treatments for people with multiple myeloma, a blood cancer, that has come back or stopped responding to previous therapies. It will compare two new experimental drug combinations against current standard treatments. The trial will enroll about 795 …

This early-stage study is testing a new combination of two experimental drugs for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals are to find a safe and effective dose of the two drugs used together and to …

This study follows 380 patients with advanced non-small cell lung cancer who have specific genetic mutations. Researchers will track how well patients do when receiving approved amivantamab-containing treatments in real-world clinical settings, not in controlled trials. The study…

This is the first time researchers are testing a new experimental drug called JNJ-79635322 in people. The main goal is to find a safe dose for future studies. The trial is for adults with advanced multiple myeloma or AL amyloidosis, two serious blood disorders, who have already t…

This study aims to see if adding newer drugs (teclistamab or talquetamab) to a standard treatment works better for controlling newly diagnosed multiple myeloma. It will involve about 1,590 adults who are not planning to have a stem cell transplant. The main goal is to see if thes…

This study is testing a new drug called icotrokinra for people with moderate to severe Crohn's disease, a chronic inflammatory bowel condition. It will involve about 1,100 participants to see if the drug can reduce symptoms and heal intestinal inflammation better than a placebo. …

This study is testing a new device called TAR-210, which is placed in the bladder to slowly release a cancer drug called erdafitinib. The goal is to treat bladder cancer directly at the site, potentially controlling the disease while reducing side effects that can happen when the…

This study is testing whether an experimental drug called JNJ-77242113 (icotrokinra) can reduce joint pain, swelling, and skin symptoms in people with active psoriatic arthritis who have already tried at least one other biologic medication. About 750 participants will be randomly…

This early-stage study is testing a new drug called JNJ-79635322 when combined with existing multiple myeloma treatments. Researchers aim to find safe and effective doses for 140 participants with different treatment histories. The trial will closely monitor side effects and how …

This early-stage study is testing a new drug called bleximenib in people with acute leukemia that has come back or not responded to other treatments. The first goal is to find a safe and effective dose. The second goal is to see if this dose can help patients achieve remission, w…

This study is checking how well the medication guselkumab works for people with active psoriatic arthritis in everyday medical practice. It will follow 200 participants for up to a year, using special ultrasound imaging to measure inflammation in their joints and tendons. The mai…

This is the first human study of a new experimental drug called JNJ-95566692, a triple-target antibody designed to fight B-cell non-Hodgkin lymphoma. The main goal is to find safe and tolerable doses, both alone and when combined with another drug, for people whose cancer has ret…

This study is testing whether adding a new drug called bleximenib to a standard two-drug treatment works better for older adults with a specific type of acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. It will involve about 600 participants and compare t…

This study is testing a new drug called JNJ-79635322 to see if it works better than an existing treatment for multiple myeloma, a type of blood cancer. It is for people whose cancer has come back or stopped responding after trying at least three other types of therapy. The main g…

This study is testing if adding a new drug, amivantamab, to standard chemotherapy and immunotherapy works better for advanced head and neck cancer that has returned or spread. It will involve about 500 adults who have not yet received treatment for their advanced cancer. The main…

This study is testing a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or is no longer responding to other treatments. The main goals are to see if the drug is effective at controlling the cancer and to check how safe it is…

This study is testing a medication called guselkumab to see if it can help children and teenagers with moderate to severe Crohn's disease. It aims to reduce their symptoms and heal the inflammation seen inside their intestines. The trial will involve about 120 young participants …

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This study is testing whether adding a newer drug called amivantamab to standard chemotherapy works better than the current standard treatment (cetuximab plus chemotherapy) for people with advanced left-sided colon or rectal cancer that has spread and cannot be removed by surgery…

This early-stage study is testing a new two-drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to find a safe and tolerable dose of the drugs working together and to see how well the body h…

This study is testing an investigational drug called nipocalimab to see if it can reduce symptoms and improve daily life for adults with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes severe muscle weakness. About 199 participants will be randomly a…

This early-stage study is testing a new drug, JNJ-78278343, that aims to guide the body's own immune cells to attack prostate cancer. It is being given in combination with other standard treatments like immunotherapy, chemotherapy, or hormone therapy. The main goals are to find a…

This study aims to see if a drug called bedaquiline is safe and works well for children and teenagers with a hard-to-treat form of tuberculosis (MDR-TB). Researchers will give bedaquiline along with other standard TB drugs to up to 60 participants, from newborns to under 18 years…

This study is testing whether an investigational drug called nipocalimab works better than the current standard treatment (IVIG) to prevent severe bleeding and low platelet counts in babies at risk of a rare immune condition called FNAIT. It will enroll about 50 pregnant women wh…

This study is testing whether an experimental drug called JNJ-89495120 can reduce depression symptoms better than a placebo. Researchers will enroll 124 adults with major depressive disorder and measure changes in their symptoms over just 5 days. The trial is designed to see if t…

This study is testing a modified version of a CAR-T cell therapy called cilta-cel for people newly diagnosed with multiple myeloma who cannot receive a stem cell transplant. It aims to see if changing how the therapy is prepared and given can make it work better and be safer. The…

This is the first study in people to test a new drug called JNJ-88549968 for blood cancers with a specific genetic change (CALR mutation). The main goals are to find a safe dose and understand how the body handles the drug. The drug works by guiding a patient's own immune cells t…

This study is testing if an experimental drug called pasritamig, when added to standard supportive care, helps men with advanced prostate cancer live longer compared to supportive care alone. It will involve about 663 men whose cancer has spread and is no longer responding to sta…

This study compares two experimental drugs, nipocalimab and efgartigimod, for adults with generalized myasthenia gravis—an autoimmune disease that causes severe muscle weakness. Researchers want to see which drug better reduces harmful antibodies and improves daily activities lik…

This study is testing a new type of personalized immune cell therapy called prizlo-cel for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments, or for those with newly diagnosed high-risk disease. The therapy involves collecting a pat…

This early-stage study is testing a new experimental drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be surgically removed. The main goals are to find a safe dose and understand how the body handles the drug. The trial is enrolling 200 adu…

This study is testing an investigational drug called nipocalimab to see if it can prevent severe fetal anemia in pregnant women at high risk for a serious blood condition called Hemolytic Disease of the Fetus and Newborn (HDFN). The goal is to help babies avoid dangerous complica…

This early-stage trial is testing a new experimental drug called JNJ-95437446 in people with advanced solid tumors, including colorectal, lung, and head/neck cancers. The study aims to find safe doses and check for side effects in 380 participants. Researchers will also gather in…

This early-stage study is testing a new experimental drug called JNJ-89862175 for people with advanced solid tumors that have spread or cannot be surgically removed. The trial aims to find safe and effective doses by enrolling 360 participants with specific cancers including lung…

This is the first study in people of an experimental drug called JNJ-89402638 for advanced colorectal and stomach cancers that have spread and stopped responding to standard treatments. The main goals are to find a safe dose and see how the body handles the drug, both alone and w…

This study is testing an investigational drug called nipocalimab in children and teenagers with generalized myasthenia gravis (gMG), a rare disease that causes severe muscle weakness. The main goals are to see how the drug behaves in the body, if it is safe, and if it can help re…

This study is testing a new drug called amivantamab, both by itself and when added to standard chemotherapy, for people with advanced colorectal cancer that has spread. The main goals are to see if the drug helps shrink tumors and to understand its safety. Researchers will enroll…

This study is testing a new, easier-to-administer injection version of the drug amivantamab for people with advanced non-small cell lung cancer. It aims to see how well the injected drug shrinks tumors and how safe it is, either alone or combined with other treatments. The trial …

This study is testing whether an experimental drug called nipocalimab can better control moderate to severe lupus compared to a placebo. It will involve 600 adults with active lupus over 52 weeks. The main goal is to see if the drug reduces overall disease activity while allowing…

This is the first study in people to test a new drug called JNJ-87562761. It aims to find a safe dose and see how well it works for adults with multiple myeloma, a blood cancer, that has come back or stopped responding to other treatments. The main goal is to check for side effec…

This early-stage trial is testing a new two-drug combination for men with advanced prostate cancer that has spread. The main goal is to find safe dose levels and check for side effects. Researchers will also look for early signs that the treatment might help control the cancer.

This large, late-stage study is testing a pill called icotrokinra to see if it can bring and keep ulcerative colitis under control. It will involve about 882 adults and teenagers whose current treatments aren't working well enough. The main goal is to see if the drug can put the …

This study is testing a new combination of two drugs, amivantamab and olomorasib, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find the safest and most effective dose of the drug pair and to see how…

This study follows 150 people with early-stage bladder cancer who have already started treatment with TAR-200 in real-world medical settings. The main goal is to see how long patients stay cancer-free after starting this treatment and to monitor how the treatment is actually used…

This study is comparing a new drug combination to the current standard treatment for advanced colorectal cancer that has returned or spread after initial chemotherapy. It aims to see if adding the drug amivantamab to a common chemotherapy regimen helps patients live longer withou…

This study is testing whether an injectable medication called guselkumab can reduce back pain and spinal inflammation in people with active psoriatic arthritis. About 405 participants who have not tried biologic drugs will receive either the medication or a placebo for 24 weeks, …

This study is testing a new, long-acting drug implant called TAR-210 that is placed directly into the bladder. It is for people with a specific type of high-risk bladder cancer that has come back after standard BCG treatment. The goal is to see if this new implant works better an…

This study allows multiple myeloma patients who benefited from daratumumab treatment in previous Janssen trials to continue receiving it. The main goal is to provide ongoing treatment access while monitoring long-term safety. About 500 participants who are already responding well…

This study is testing whether an investigational drug called nipocalimab can prevent a serious bleeding condition in newborns. It is for pregnant women who have had a previous baby affected by this immune disorder. The goal is to see if giving the drug to the mother during pregna…

This study is testing whether a new oral medication called milvexian can safely prevent a second stroke in people who recently had an ischemic stroke or a high-risk mini-stroke (TIA). It will involve 15,000 participants who will take either milvexian or a placebo pill, in additio…

This study is testing whether a nasal spray called esketamine, when added to standard mental health care, can quickly reduce severe depression and suicidal thoughts in teenagers. It will compare the spray to a placebo (a look-alike treatment with no active drug) in about 258 teen…

This study aims to find the best way to prevent taste changes (dysgeusia) that can occur when taking the myeloma drug talquetamab. About 130 adults with relapsed or hard-to-treat multiple myeloma will try different preventive treatments. Researchers will carefully measure taste c…

This study is testing whether a more intensive skin care plan can reduce severe rashes and nail problems in people with a specific type of advanced lung cancer. The 300 participants are starting treatment with two targeted drugs, amivantamab and lazertinib, which are known to cau…

This study aims to better understand sleep in people with major depression, particularly those who also have insomnia. Researchers will use a comfortable headband that records brain activity during sleep at home, and compare it with participants' own reports about their sleep qua…

This study is not a treatment trial. Its purpose is to monitor the long-term health of people who have already received a specific CAR-T cell therapy (cilta-cel) for multiple myeloma. Researchers will follow about 295 participants for up to 15 years to check for any delayed side …

This early-stage study aims to understand how the body absorbs, breaks down, and eliminates the experimental drug bleximenib in people with acute leukemia. Researchers will give a small, traceable radioactive version of the drug to 10 participants with specific types of advanced …

This study is creating a global registry to track pregnancies at risk for hemolytic disease of the fetus and newborn (HDFN), a blood condition where a mother's and baby's incompatible blood types cause rapid red blood cell breakdown. Researchers will follow 175 pregnant participa…